OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Psychiatry is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Treating Pathologies of the Will	278
Evaluating Associations Between Cannabis and Heroin Use	214
Broadening the Parameters of Clinical High Risk for Psychosis	173
2024 Annual Meeting: Presidential Address	166
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	156
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	153
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	139
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	122
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	117
Depression, Inflammation, and Postpartum Psychosis	113
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	110
Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions	108
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	106
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	106
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	101
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	94
Reconsidering the Interpretive Basis of Neural Efficiency as a Biomarker in Pediatric Anxiety: Response to Ai and Colleagues	90
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial	86
Correcting Overestimations in Self-Harm Visit Data	84
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	83
Correction to Poirot et al.	80
Corrigendum to Morley et al.	78
2024 Annual Meeting: CEO and Medical Director’s Address	76
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	75
The First Large GWAS Meta-Analysis for Postpartum Depression	74

Highlights From the Residents’ Journal: September 2024	73
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	70
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	69
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	68
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	68
Familial Risk of Postpartum Psychosis	66
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	65
New Insights Into Psychotic Disorders	62
Highlights From the Residents’ Journal: March 2026	61
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	58
Sex Differences in Psychiatric Comorbidity Among Adults With Substance Use Disorders	58
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	57
Suicide and the Menstrual Cycle	57
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	57
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	56
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	55
Trauma and Adverse Outcomes: Cause, Consequence, or Shared Vulnerability?	54
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	54
A Proposed Expansion of the Definition of Treatment-Resistant Schizophrenia	53
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	53
A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial	52
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	52
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	50
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	50
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	50
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	50
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	50